By Colin Kellaher

Pfizer Inc. (PFE) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval Vyndaqel for the treatment of wild-type or hereditary transthyretin amyloidosis in adults with cardiomyopathy, or ATTR-CM.

The New York drug maker said Vyndaqel, if approved by the European Commission, would be the first pharmacologic therapy in the EU for ATTR-CM, a rare, life-threatening disease characterized by the buildup of abnormal deposits of misfolded protein called amyloid in the heart.

The European Commission, which generally follows the CHMP's recommendations, will review the recommendation, with a final decision expected in the coming months, Pfizer said.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 13, 2019 08:57 ET (13:57 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Pfizer.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Pfizer.